Physician profile
Neha Damle
NPI 1124462544
$3,919.28
in general payments reported to CMS, 2019-2025
48 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $681 · 2022: $210 · 2023: $928 · 2024: $860 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.25 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $492.18 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $409.36 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Lilly USA, LLC | $345.01 | 2021-2025 | Verzenio, Jaypirca |
| Janssen Biotech, INC. | $237.53 | 2022-2024 | Akeega, Erleada, Balversa |
| Genzyme Corporation | $195.42 | 2021-2025 | |
| Amgen INC. | $194.67 | 2021-2025 | Kyprolis, Blincyto, Vectibix |
| Genentech USA, INC. | $191.17 | 2023-2025 | Polivy, Phesgo, Itovebi |
| Merck Sharp & Dohme LLC | $131.49 | 2022-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $127.54 | 2023-2025 | Ninlaro, Iclusig |
| Novartis Pharmaceuticals Corporation | $109.78 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $107.44 | 2023-2024 | Opdivo, Augtyro |
| Celgene Corporation | $106.01 | 2023-2025 | Opdivo, Reblozyl |
| Daiichi Sankyo INC. | $91.40 | 2022-2025 | Datroway, Enhertu |
| Incyte Corporation | $77.04 | 2022-2025 | Niktimvo, Jakafi, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $75.07 | 2023 | Imbruvica, Epkinly |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Damle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.